ALEAF:OTC-Aleafia Health Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.05

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.04M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ALEAF Stock Forecast & Price:
Based on the Aleafia Health Inc stock forecasts from 0 analysts, the average analyst target price for Aleafia Health Inc is not available over the next 12 months. Aleafia Health Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aleafia Health Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Aleafia Health Inc’s stock price was USD 0.05. Aleafia Health Inc’s stock price has changed by +2.06% over the past week, -16.95% over the past month and -84.04% over the last year.

About Aleafia Health Inc (ALEAF:OTC)

Aleafia Health Inc. operates as a cannabis health and wellness products and services company in Canada and internationally. Its product portfolio includes cannabis oils, capsules, edibles, cannabis-infused sublingual strips, and vape cartridges, as well as bath products. In addit ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY Merck KGaA ADR

N/A

USD75.83B 22.80 14.02
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD75.48B 22.76 14.02
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD43.26B 26.04 0.07
HLUYY H Lundbeck A/S ADR

N/A

USD19.86B 25.64 3.17
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD15.85B 15.06 2.54
SGIOF Shionogi & Co. Ltd

N/A

USD15.13B 18.12 0.08
SGIOY Shionogi & Co Ltd ADR

N/A

USD15.13B 18.19 0.08
ESALY Eisai Co Ltd ADR

N/A

USD12.21B 34.90 0.11
ESALF Eisai Co. Ltd

N/A

USD12.02B 32.52 0.11
GNHAF Vifor Pharma AG

N/A

USD11.60B 73.41 17.55

ETFs Containing ALEAF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -46.93% 39% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.93% 39% F 21% F
Trailing 12 Months  
Capital Gain -84.04% 27% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.04% 27% F 13% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.66% 21% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.66% 21% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 47.16% 73% C 51% F
Risk Adjusted Return -56.53% 20% F 9% F
Market Capitalization 0.02B 67% D+ 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.50 84% B 95% A
Price/Book Ratio 0.32 80% B- 87% B+
Price / Cash Flow Ratio -0.59 48% F 65% D
EV/EBITDA -0.48 51% F 62% D-
Management Effectiveness  
Return on Equity -197.06% 23% F 8% F
Return on Invested Capital 2.70% 63% D 49% F
Return on Assets -24.35% 41% F 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.38 36% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.